Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease : From Molecular Pathophysiology to Personalized Medicine
Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left ventricular wall thickness not solely explained by abnormal loading conditions. It is often genetically determined, with sarcomeric gene mutations accounting for around 50% of cases. Several conditions, including syndromic, metabolic, infiltrative, and neuromuscular diseases, may present with left ventricular hypertrophy, mimicking the hypertrophic cardiomyopathy phenotype but showing a different pathophysiology, clinical course, and outcome. Despite being rare, they are collectively responsible for a large proportion of patients presenting with hypertrophic heart disease, and their timely diagnosis can significantly impact patients' management. The understanding of disease pathophysiology has advanced over the last few years, and several therapeutic targets have been identified, leading to a new era of tailored treatments applying to different etiologies associated with left ventricular hypertrophy. This review aims to provide an overview of the existing and emerging therapies for the principal causes of hypertrophic heart disease, discussing the potential impact on patients' management and clinical outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Circulation. Heart failure - 16(2023), 8 vom: 01. Aug., Seite e010687 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Monda, Emanuele [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Amyloidosis |
|---|
| Anmerkungen: |
Date Completed 17.08.2023 Date Revised 25.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCHEARTFAILURE.123.010687 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359774229 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359774229 | ||
| 003 | DE-627 | ||
| 005 | 20231226081607.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCHEARTFAILURE.123.010687 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359774229 | ||
| 035 | |a (NLM)37477018 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Monda, Emanuele |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Targeted Therapies in Pediatric and Adult Patients With Hypertrophic Heart Disease |b From Molecular Pathophysiology to Personalized Medicine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2023 | ||
| 500 | |a Date Revised 25.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Hypertrophic cardiomyopathy is a myocardial disease defined by an increased left ventricular wall thickness not solely explained by abnormal loading conditions. It is often genetically determined, with sarcomeric gene mutations accounting for around 50% of cases. Several conditions, including syndromic, metabolic, infiltrative, and neuromuscular diseases, may present with left ventricular hypertrophy, mimicking the hypertrophic cardiomyopathy phenotype but showing a different pathophysiology, clinical course, and outcome. Despite being rare, they are collectively responsible for a large proportion of patients presenting with hypertrophic heart disease, and their timely diagnosis can significantly impact patients' management. The understanding of disease pathophysiology has advanced over the last few years, and several therapeutic targets have been identified, leading to a new era of tailored treatments applying to different etiologies associated with left ventricular hypertrophy. This review aims to provide an overview of the existing and emerging therapies for the principal causes of hypertrophic heart disease, discussing the potential impact on patients' management and clinical outcome | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fabry disease | |
| 650 | 4 | |a Friedreich ataxia | |
| 650 | 4 | |a amyloidosis | |
| 650 | 4 | |a cardiomyopathy | |
| 650 | 4 | |a glycogen storage disease | |
| 650 | 4 | |a hypertrophy | |
| 700 | 1 | |a Bakalakos, Athanasios |e verfasserin |4 aut | |
| 700 | 1 | |a Rubino, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Verrillo, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Diana, Gaetano |e verfasserin |4 aut | |
| 700 | 1 | |a De Michele, Gianantonio |e verfasserin |4 aut | |
| 700 | 1 | |a Altobelli, Ippolita |e verfasserin |4 aut | |
| 700 | 1 | |a Lioncino, Michele |e verfasserin |4 aut | |
| 700 | 1 | |a Perna, Alessia |e verfasserin |4 aut | |
| 700 | 1 | |a Falco, Luigi |e verfasserin |4 aut | |
| 700 | 1 | |a Palmiero, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Elliott, Perry M |e verfasserin |4 aut | |
| 700 | 1 | |a Limongelli, Giuseppe |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation. Heart failure |d 2008 |g 16(2023), 8 vom: 01. Aug., Seite e010687 |w (DE-627)NLM187215812 |x 1941-3297 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:e010687 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCHEARTFAILURE.123.010687 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 8 |b 01 |c 08 |h e010687 | ||